VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
BWAYBrainsWay Ltd.
$14.89$584M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

BWAY logoBrainsWay Ltd.(BWAY)Earnings, Financials & Key Ratios

BWAY•NASDAQ
40.0× P/E·Price updated Jun 17, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryNeuromodulation and neuro devices
AboutBrainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Show more
  • Revenue$52M+27.3%
  • EBITDA$6M+85.4%
  • Net Income$8M+161.3%
  • EPS (Diluted)0.36+300.0%
  • Gross Margin75.42%+1.1%
  • EBITDA Margin11.22%+45.6%
  • Operating Margin8.28%+144.1%
  • Net Margin14.62%+105.2%
  • ROE11.26%+100.3%

BWAY Key Insights

BrainsWay Ltd. (BWAY) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong Piotroski F-Score: 7/9
  • ✓FCF machine: 31.4% free cash flow margin
  • ✓Momentum leader: RS Rating 88 (top 12%)
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 18.8%

✗Weaknesses

  • ✗Weak 3Y average ROE of 2.4%
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when BWAY posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BWAY Price & Volume

BrainsWay Ltd. (BWAY) stock price & volume — 10-year historical chart

Loading chart...

BWAY Growth Metrics

BrainsWay Ltd. (BWAY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years22.61%
5 Years18.81%
3 Years24.33%
TTM29.37%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM125.07%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM188.78%

Return on Capital

10 Years-16.24%
5 Years-6.63%
3 Years-0.62%
Last Year5.09%

BWAY Recent Earnings

BrainsWay Ltd. (BWAY) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (91%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.12+140.0%
$0.05
Rev
$16M+6.1%
$15M
Q2 2026
Mar 11, 2026
Metric
Actual
Est
EPS
$0.14+133.3%
$0.06
Rev
$15M+3.8%
$14M
Q4 2025
Nov 11, 2025
Metric
Actual
Est
EPS
$0.08-27.3%
$0.11
Rev
$14M-3.6%
$14M
Q4 2025
Sep 30, 2025
Metric
Actual
Est
EPS
$0.05
—
Rev
$13M
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.12vs $0.05+140.0%
$16Mvs $15M+6.1%
Q2 2026Mar 11, 2026
$0.14vs $0.06+133.3%
$15Mvs $14M+3.8%
Q4 2025Nov 11, 2025
$0.08vs $0.11-27.3%
$14Mvs $14M-3.6%
Q4 2025Sep 30, 2025
$0.05
$13M
Based on last 12 quarters of dataView full earnings history →

BWAY Peer Comparison

BrainsWay Ltd. (BWAY) competitors in Neuromodulation and neuro devices — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
STIM logoSTIMNeuronetics, Inc.Direct Competitor84.2M1.21-2.0599.17%-24.48%-139.83%3.44
NVCR logoNVCRNovoCure LimitedDirect Competitor2.03B17.85-14.638.28%-25.66%-50.82%0.85
LIVN logoLIVNLivaNova PLCProduct Competitor4.31B78.50-17.6410.74%7.47%9.13%0.39
GKOS logoGKOSGlaukos CorporationProduct Competitor7.46B127.41-38.8432.33%-34.34%-26.46%0.21
ELMD logoELMDElectromed, Inc.Product Competitor307.52M37.1443.1916.97%14.08%22.14%0.00
ABT logoABTAbbott LaboratoriesSupply Chain153.82B88.4611.584.59%31.88%27.26%0.32
MDT logoMDTMedtronic plcSupply Chain100.32B78.1421.653.62%13%9.49%0.59
BSX logoBSXBoston Scientific CorporationSupply Chain66.8B44.9523.1719.87%14.4%12.4%0.51

Compare BWAY vs Peers

BrainsWay Ltd. (BWAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs STIM

Most directly comparable listed peer for BWAY.

Scale Benchmark

vs ABT

Larger-name benchmark to compare BWAY against a more recognizable public peer.

Peer Set

Compare Top 5

vs STIM, NVCR, LIVN, GKOS

BWAY Income Statement

BrainsWay Ltd. (BWAY) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
11.14M16.4M23.1M22.06M29.66M27.18M31.79M41.02M52.23M56.22M
Revenue Growth %
-3.29%47.12%40.89%-4.52%34.46%-8.36%16.96%29.04%27.33%29.37%
Cost of Goods Sold
2.6M3.59M5.13M5.06M6.6M7.13M8.31M10.44M12.84M13.77M
COGS % of Revenue
23.28%21.89%22.2%22.93%22.25%26.23%26.14%25.44%24.58%-
Gross Profit
8.55M▲ 0%
12.81M▲ 49.8%
17.97M▲ 40.3%
17M▼ 5.4%
23.06M▲ 35.6%
20.05M▼ 13.1%
23.48M▲ 17.1%
30.58M▲ 30.3%
39.39M▲ 28.8%
42.45M▲ 0%
Gross Margin %
76.72%78.11%77.8%77.07%77.75%73.77%73.86%74.56%75.42%75.51%
Gross Profit Growth %
-6.01%49.8%40.32%-5.41%35.64%-13.05%17.1%30.26%28.79%-
Operating Expenses
15.16M17.92M26.45M21.83M28.06M32.73M28.44M29.19M35.06M36.7M
OpEx % of Revenue
136.03%109.3%114.49%98.96%94.6%120.44%89.46%71.17%67.14%-
Selling, General & Admin
9.29M11.34M17.66M16M21.66M25.05M21.64M22M25.46M26.55M
SG&A % of Revenue
83.4%69.15%76.43%72.56%73.05%92.18%68.08%53.64%48.75%-
Research & Development
5.34M6.16M7.88M5.82M6.39M7.68M6.67M7.19M9.6M10.15M
R&D % of Revenue
47.94%37.54%34.09%26.4%21.56%28.25%20.97%17.53%18.39%-
Other Operating Expenses
523K427K916K000133K000
Operating Income
-6.61M▲ 0%
-5.11M▲ 22.6%
-8.48M▼ 65.7%
-4.83M▲ 43.0%
-5M▼ 3.5%
-12.68M▼ 153.7%
-4.96M▲ 60.9%
1.39M▲ 128.1%
4.32M▲ 210.8%
5.75M▲ 0%
Operating Margin %
-59.32%-31.19%-36.69%-21.89%-16.86%-46.67%-15.6%3.39%8.28%10.23%
Operating Income Growth %
-219.53%22.64%-65.74%43.03%-3.52%-153.71%60.9%128.05%210.78%-
EBITDA
-5.54M-3.89M-5.68M-3.21M-3.31M-11.15M-3.62M3.16M5.86M7.36M
EBITDA Margin %
-49.7%-23.7%-24.59%-14.56%-11.17%-41.02%-11.4%7.71%11.22%13.09%
EBITDA Growth %
-290.07%29.84%-46.19%43.48%-3.18%-236.52%67.51%187.3%85.36%97.77%
D&A (Non-Cash Add-back)
1.07M1.23M2.79M1.62M1.69M1.53M1.34M1.77M1.54M1.61M
EBIT
-6.8M-5.92M-9.51M-5.08M-6.36M-12.99M-3.9M3.59M9.92M10.96M
Net Interest Income
-112K-351K-331K-45K84K1.04M1.87M1.12M3.41M1.98M
Interest Income
22K44K175K61K225K1.11M2.17M2.48M5.64M3.52M
Interest Expense
134K395K506K106K141K68K298K1.36M2.23M1.54M
Other Income/Expense
-274K-1.16M-1.43M-319K-1.42M-351K1.01M2.07M3.39M3.1M
Pretax Income
-6.88M▲ 0%
-6.27M▲ 8.9%
-9.91M▼ 58.0%
-5.15M▲ 48.0%
-6.42M▼ 24.7%
-13.03M▼ 103.1%
-3.95M▲ 69.7%
3.46M▲ 187.7%
7.71M▲ 122.9%
8.86M▲ 0%
Pretax Margin %
-61.78%-38.24%-42.88%-23.34%-21.64%-47.96%-12.41%8.43%14.76%15.75%
Income Tax
169K209K422K237K43K315K251K538K77K40K
Effective Tax Rate %
-2.45%-3.33%-4.26%-4.6%-0.67%-2.42%-6.36%15.55%1%0.45%
Net Income
-7.05M▲ 0%
-6.48M▲ 8.2%
-10.33M▼ 59.4%
-5.38M▲ 47.9%
-6.46M▼ 20.0%
-13.35M▼ 106.6%
-4.2M▲ 68.6%
2.92M▲ 169.6%
7.63M▲ 161.3%
8.82M▲ 0%
Net Margin %
-63.29%-39.51%-44.71%-24.41%-21.79%-49.12%-13.2%7.12%14.62%15.68%
Net Income Growth %
-194.28%8.15%-59.41%47.86%-20%-106.58%68.56%169.6%161.31%125.07%
Net Income (Continuing)
-7.05M-6.48M-10.33M-5.38M-6.46M-13.35M-4.2M2.92M7.63M8.82M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-0.48▲ 0%
-0.39▲ 18.7%
-0.50▼ 28.2%
-0.24▲ 52.0%
-0.21▲ 12.5%
-0.43▼ 104.8%
-0.13▲ 69.8%
0.09▲ 169.2%
0.36▲ 300.0%
0.46▲ 0%
EPS Growth %
-182.35%18.75%-28.21%52%12.5%-104.76%69.77%169.23%300%188.78%
EPS (Basic)
-0.48-0.39-0.50-0.24-0.21-0.43-0.130.090.40-
Diluted Shares Outstanding
14.77M16.64M20.51M22.45M31.15M32.98M33.16M34.77M21.21M19.08M
Basic Shares Outstanding
14.77M16.64M20.51M22.45M31.15M32.98M33.16M33.97M19.08M19.08M
Dividend Payout Ratio
----------

BWAY Balance Sheet

BrainsWay Ltd. (BWAY) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
17.89M13.48M28.83M24.3M65.45M58.09M55.47M79.67M84.89M78.63M
Cash & Short-Term Investments
14.51M8.97M21.89M17.18M57.35M47.58M45.98M69.34M69.13M59.77M
Cash Only
14.51M8.97M21.67M16.96M16.92M47.58M10.52M69.34M67.7M58.64M
Short-Term Investments
00221K221K40.43M035.47M01.43M1.14M
Accounts Receivable
2.93M3.97M5.96M5.79M6.33M4.84M3.78M4.6M4.11M7.53M
Days Sales Outstanding
95.8388.4694.1195.8177.9365.0643.4140.928.7333.5
Inventory
271K91K306K442K200K3.84M3.72M4.43M7.13M7.08M
Days Inventory Outstanding
38.129.2521.7831.911.06196.45163.3154.81202.81151.23
Other Current Assets
507K1.07M0212K388K1.83M691K1.3M4.51M4.24M
Total Non-Current Assets
9.14M10.12M9.91M9.71M10.29M6.39M7.51M14.65M28.03M38.37M
Property, Plant & Equipment
7.09M7.63M15.23M9.55M9.33M5.35M5.79M11.95M12.17M12.91M
Fixed Asset Turnover
1.57x2.15x1.52x2.31x3.18x5.08x5.49x3.43x4.29x4.30x
Goodwill
0000000000
Intangible Assets
18K000000000
Long-Term Investments
0000000014.34M55.06M
Other Non-Current Assets
2.03M2.5M-5.32M163K954K766K1.72M1.64M1.52M2.31M
Total Assets
27.03M▲ 0%
23.6M▼ 12.7%
38.74M▲ 64.1%
34.01M▼ 12.2%
75.73M▲ 122.7%
64.48M▼ 14.9%
62.97M▼ 2.3%
94.32M▲ 49.8%
112.92M▲ 19.7%
117M▲ 0%
Asset Turnover
0.41x0.69x0.60x0.65x0.39x0.42x0.50x0.43x0.46x0.49x
Asset Growth %
35.39%-12.68%64.12%-12.2%122.67%-14.86%-2.33%49.77%19.72%163.29%
Total Current Liabilities
6.13M8.34M6.72M6.8M9.07M8.14M9.76M15.35M22.16M23.55M
Accounts Payable
1.63M2.24M1.32M781K1.1M1.12M758K2.87M2.43M2.93M
Days Payables Outstanding
229.41228.1193.9456.3660.9557.1433.3100.3269.0362
Short-Term Debt
0750K00000000
Deferred Revenue (Current)
2.45M1.33M1.3M1.54M2.19M1.48M05.73M12.23M40.97M
Other Current Liabilities
2.88M2.12M1.93M1.68M2.12M2.92M4.07M2.72M00
Current Ratio
2.92x1.62x4.29x3.57x7.22x7.14x5.68x5.19x3.83x3.34x
Quick Ratio
2.87x1.61x4.25x3.51x7.20x6.66x5.30x4.90x3.51x3.04x
Cash Conversion Cycle
-95.46-130.421.9571.3528.04204.37173.4195.4162.52122.73
Total Non-Current Liabilities
8.18M8.31M7.8M7.58M9.34M10.94M11.63M16.66M17.53M17.65M
Long-Term Debt
2.73M2.08M00000000
Capital Lease Obligations
000243K254K254K239K4.8M5.74M22.27M
Deferred Tax Liabilities
112K140K00000000
Other Non-Current Liabilities
5.34M6.09M5.45M5.56M5.93M6.02M6.08M2.43M00
Total Liabilities
14.31M16.65M14.52M14.38M18.41M19.08M21.39M32M39.7M41.2M
Total Debt
2.73M2.83M414K672K754K488K471K5.62M6.82M6.71M
Net Debt
-11.78M-6.13M-21.26M-16.29M-16.17M-47.09M-10.05M-63.72M-60.88M-51.93M
Debt / Equity
0.21x0.41x0.02x0.03x0.01x0.01x0.01x0.09x0.09x0.09x
Debt / EBITDA
-------1.78x1.16x0.91x
Net Debt / EBITDA
--------20.15x-10.39x-7.05x
Interest Coverage
-50.73x-14.98x-18.79x-47.94x-45.10x-191.00x-13.08x2.64x4.45x7.13x
Total Equity
12.72M▲ 0%
6.95M▼ 45.4%
24.22M▲ 248.4%
19.63M▼ 18.9%
57.33M▲ 192.0%
45.4M▼ 20.8%
41.58M▼ 8.4%
62.31M▲ 49.9%
73.22M▲ 17.5%
75.8M▲ 0%
Equity Growth %
23.66%-45.35%248.39%-18.93%191.97%-20.81%-8.41%49.86%17.51%154.06%
Book Value per Share
0.860.421.180.871.841.381.251.793.453.97
Total Shareholders' Equity
12.72M6.95M24.22M19.63M57.33M45.4M41.58M62.31M73.22M75.8M
Common Stock
171K171K233K233K363K364K367K413K430K439K
Retained Earnings
-55.1M-61.58M-71.91M-77.29M-83.76M-97.11M-101.3M-98.38M-90.75M-88.52M
Treasury Stock
0000000000
Accumulated OCI
-1.27M-2.19M-2.19M1.56M-2.19M-2.19M-2.19M-2.19M-2.19M-2.19M
Minority Interest
0000000000

BWAY Cash Flow Statement

BrainsWay Ltd. (BWAY) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-3.47M-3.77M-7.24M-1.44M884K-9.76M1.28M10.3M18.16M14.19M
Operating CF Margin %
-31.11%-23.01%-31.36%-6.51%2.98%-35.91%4.04%25.11%34.78%-
Operating CF Growth %
-44.34%-8.83%-92%80.18%161.56%-1204.07%113.16%702.02%76.37%581.34%
Net Income
-7.05M-6.48M-10.33M-5.38M-6.46M-13.35M-4.2M2.92M7.69M8.82M
Depreciation & Amortization
1.07M1.23M1.6M1.62M1.69M1.53M1.34M1.77M1.55M1.61M
Stock-Based Compensation
1.03M710K1.26M799K1.89M1.47M381K1.42M0569K
Deferred Taxes
169K209K422K237K43K315K251K00189K
Other Non-Cash Items
230K763K1.95M1.12M2.66M1.72M1.88M1.8M1.27M-1.25M
Working Capital Changes
1.09M-204K-2.15M179K1.07M-1.45M1.64M2.39M7.65M4.23M
Change in Receivables
-21K-419K-2.5M-104K-849K1.46M1.09M-867K611.82K-491.18K
Change in Inventory
276K-330K00-411K-3.6M-506K-920K-2M-2.03M
Change in Payables
310K859K175K-552K289K0-327K2.12M-480.78K-764.78K
Cash from Investing
-2.45M-1.14M-2.45M-2.46M-42.22M42.17M-37.41M30.31M-17.63M-24.87M
Capital Expenditures
-985K-1.97M-3.31M-2.47M-2.24M1.94M-2.39M-4.76M-1.76M-1.47M
CapEx % of Revenue
8.84%12.03%14.33%11.2%7.55%7.12%7.51%11.62%3.37%2.61%
Acquisitions
000039.98M00000
Investments
----------
Other Investing
-2M1.01M00-39.98M0-35.02M35.08M03.3M
Cash from Financing
11.11M-265K22.47M-1.03M41.52M-1.55M-1.03M18.26M-2.23M-2.37M
Debt Issued (Net)
2.7M0-3.43M-417K-475K-533K-271K-424K0-637K
Equity Issued (Net)
8.45M026.33M042.26M-52K016.35M00
Dividends Paid
0000000000
Share Repurchases
00000-52K0000
Other Financing
-39K-265K-425K-613K-269K-962K-755K2.33M-2.23M-1.73M
Net Change in Cash
5.33M▲ 0%
-5.54M▼ 203.9%
12.71M▲ 329.3%
-4.71M▼ 137.1%
-40K▲ 99.2%
30.66M▲ 76750.0%
-37.06M▼ 220.9%
58.83M▲ 258.7%
-1.67M▼ 102.8%
-12.97M▲ 0%
Free Cash Flow
-4.45M▲ 0%
-5.75M▼ 29.0%
-10.55M▼ 83.7%
-3.91M▲ 63.0%
-1.35M▲ 65.3%
-9.76M▼ 620.8%
-1.1M▲ 88.7%
6.5M▲ 689.7%
16.4M▲ 152.2%
12.72M▲ 0%
FCF Margin %
-39.95%-35.04%-45.69%-17.71%-4.57%-35.91%-3.47%15.86%31.41%22.63%
FCF Growth %
-58.43%-29.04%-83.73%62.99%65.34%-620.83%88.7%689.66%152.18%58.71%
FCF per Share
-0.30-0.35-0.51-0.17-0.04-0.30-0.030.190.770.67
FCF Conversion (FCF/Net Income)
0.49x0.58x0.70x0.27x-0.14x0.73x-0.31x3.53x2.38x1.44x
Interest Paid
0000000125K00
Taxes Paid
0000000000

BWAY Key Ratios

BrainsWay Ltd. (BWAY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-61.32%-65.87%-66.26%-24.56%-16.79%-25.99%-9.65%5.62%11.26%12.28%
Return on Invested Capital (ROIC)
-346.49%-436.85%-336.62%-114.88%-16.85%-48.21%-24.93%6.93%59.33%35.28%
Gross Margin
76.72%78.11%77.8%77.07%77.75%73.77%73.86%74.56%75.42%75.51%
Net Margin
-63.29%-39.51%-44.71%-24.41%-21.79%-49.12%-13.2%7.12%14.62%15.68%
Debt / Equity
0.21x0.41x0.02x0.03x0.01x0.01x0.01x0.09x0.09x0.09x
Interest Coverage
-50.73x-14.98x-18.79x-47.94x-45.10x-191.00x-13.08x2.64x4.45x7.13x
FCF Conversion
0.49x0.58x0.70x0.27x-0.14x0.73x-0.31x3.53x2.38x1.44x
Revenue Growth
-3.29%47.12%40.89%-4.52%34.46%-8.36%16.96%29.04%27.33%29.37%
Related:BWAY Dividend History·BWAY Revenue History·BWAY Price History·BWAY P/E History·BWAY Financial Ratios·BWAY Institutional Holders

BWAY Frequently Asked Questions

BrainsWay Ltd. (BWAY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

BrainsWay Ltd. (BWAY) reported $56.2M in revenue for fiscal year 2025. This represents a 15334% increase from $0.4M in 2012.

BrainsWay Ltd. (BWAY) grew revenue by 27.3% over the past year. This is strong growth.

Yes, BrainsWay Ltd. (BWAY) is profitable, generating $8.8M in net income for fiscal year 2025 (14.6% net margin).

Dividend & Returns

BrainsWay Ltd. (BWAY) has a return on equity (ROE) of 11.3%. This is reasonable for most industries.

BrainsWay Ltd. (BWAY) generated $12.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in BWAY back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →

How much would $100/month in BWAY be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →